Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Microfluidic Chip Enables Simultaneous Diagnosis of COVID-19 and Influenza Diseases

By LabMedica International staff writers
Posted on 06 Jan 2022

A research team has developed a microfluidic chip that is capable of simultaneous diagnosis of COVID-19 and influenza diseases, by applying the microfluidic chip technologies. More...

Researchers from the Toyohashi University of Technology (Toyohashi, Japan) and Jikei University School of Medicine (Tokyo, Japan) built a theoretical model that manipulates microfluidic flow with an extremely simple microchannel design and has established an optimal design theory for microfluidic chips. Further, by using the diagnostic device they developed, they performed genetic amplification experiments on four types of infectious diseases, including COVID-19, and demonstrated that multiplexed rapid and simultaneous diagnosis was possible within 30 minutes. The device can be utilized for genetic diagnoses in a range of fields (e.g. agriculture, farming, and fisheries industries, food industry, and health and medical care), not only human infectious diseases. The diagnostic technology can enable anyone, anywhere, any time to detect viral diseases in a rapid, simple, and low-cost way.

The LAMP (Loop-Mediated Isothermal Amplification) method is a genetic test technology. This simple test method does not require an expensive accurate temperature control equipment, etc., in contrast to the widespread PCR test, and can be conducted on site because it allows genetic amplification at a constant temperature for a constant length of time (60 to 65℃, 30 minutes to an hour or so). However, to diagnose multiple types of viruses, the conventional LAMP method entails considerable effort to perform as many preparations of samples and reagents and genetic amplification reactions as the number of analytes, requiring expert knowledge and skills.

Therefore, the research team developed a polydimethylsiloxane (PDMS)-based multiplexed genetic diagnostic device (size: 45mm x 25mm, reaction chamber: 3µL x 5 pieces) by applying the microfluidic chip technology. It autonomously, equally, and accurately dispenses samples and reagent into an array of reaction chambers simply by introducing the liquid, a mixture of an extremely small amount of sample extracted from the analytes and a reagent, into the diagnostic device. By heating the device in warm water (at 60 to 65℃, for 30 minutes to an hour or so), it is capable of simultaneous diagnosis of multiple types of viruses with only one operation (one work process per sample).

The genetic diagnosis result showed that four types of infectious diseases including the COVID-19 (seasonal influenza A, SARS, and influenza H1N1 pdm09) were successfully detected with this diagnosis device. Only the reaction chamber that reacted when a sample containing the gene of each virus was introduced turned sky blue (denoting a positive reaction) after 30 minutes, which means that visual detection is possible.

In addition, to support on-site diagnoses, the team has developed a smartphone app, which automatically diagnoses the reaction as positive or negative based on photographs taken with a smartphone camera. The diagnosis device is capable of easy automatic test result diagnosis (positive or negative), by placing the device after LAMP reaction in a simple LED illumination device and taking photographs with a smartphone. As a result, it is expected that anyone will be able to easily perform the test, anywhere and anytime. In the future, aiming to commercialize the diagnosis device, the research team will develop devices capable of multiplexed rapid diagnosis of variants of the COVID-19 and human infectious diseases for a safe life during and after the COVID-19 pandemic.

Related Links:
Toyohashi University of Technology 
Jikei University School of Medicine 


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.